Published on October 26, 2009 at 8:57 AM
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.
The company will hold a conference call on Tuesday, October 27th at 11 a.m. eastern time to discuss the data presented at the conference. Interested parties may access the call by dialing (877) 407-0778 domestically, or (201) 689-8565 internationally. A replay of the call will be available until November 10, 2009, and can be accessed by dialing (877) 660-6853 domestically, or (201)-612-7415 for international audiences, and using account # 286 and Conference ID #: 336119.
The call will also be available via a simultaneous live webcast, and can be accessed by visiting http://iq-vcall.incommsolutions.com and using InComm IQueue Conference Number: 00336119. Please note that webcast audiences must use Internet Explorer to access the broadcast.
Source: ImmunoCellular Therapeutics, Ltd.
0d4a1e55-93f4-4946-9b36-63dd742cf697|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Antibody, Biotechnology, Brain, Brain Tumor, Cancer, Cell, Dendritic Cell, Education, Glioblastoma, Immunization, Lung Cancer, Monoclonal Antibody, Multiple Myeloma, Neurosurgery, Ovarian Cancer, Pancreatic Cancer, Vaccine